Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are assessing how the drug rupatadine 10 mg and its active metabolites behave in the bodies of participants with kidney problems compared to those with normal kidney function. The study focuses on the drugs pharmacokinetics how it is absorbed, distributed, metabolized, and excreted, its tolerability, and safety. This open-label, non-randomized study includes adult participants with varying degrees of renal impairment and matched controls without kidney issues. Participants will receive a single 10 mg dose of rupatadine after fasting overnight. The study involves a Screening period up to 28 days before dosing, a Baseline evaluation one day before dosing, a dosing day, and an End of Study visit occurring 8 days after dosing for those with normal kidney function and 12 days for those with renal impairment. Blood samples for drug level measurements and safety assessments will be collected frequently during the study, with participants staying at the clinic from one day before dosing until 24 hours after dosing. Participants will undergo various assessments including blood draws to monitor drug levels over time and safety evaluations such as vital signs, ECGs, and laboratory tests. The study will measure detailed pharmacokinetic parameters like peak plasma concentration, half-life, and clearance of rupatadine and its metabolites. The total participation time is up to approximately 40 days, covering all study visits and assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ONL1204 in people aged 55 and older who have geographic atrophy GA related to age-related macular degeneration AMD. GA associated with AMD is a leading cause of vision loss and blindness globally, linked to aging and other risk factors. This phase 2 study aims to understand how different doses and treatment schedules of ONL1204 affect this condition. Participants will receive one of several treatments ONL1204 injections at two dose levels 100 or 200 micrograms every 12 weeks, ONL1204 200 micrograms every 24 weeks, sham injections every 12 or 24 weeks, or monthly injections of avacincaptad pegol. All injections are given into the eye intravitreal. This randomized, double-masked trial compares these different groups over a period of 48 weeks. During the study, participants will have regular visits for eye exams, imaging, and vision tests to monitor their condition and treatment effects. Researchers will track safety and efficacy outcomes throughout the 48 weeks. Participants must meet specific vision and eye health criteria to join, and safety monitoring will continue throughout the treatment period to ensure participant well-being.